 | |
| Company type | Subsidiary (formerly: Public) |
|---|---|
| Nasdaq: CBST | |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992 |
| Defunct | 2015 |
| Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez, President, CEO; |
| Products | Product Pipeline |
| Revenue |  $926.4 million USD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.
.[1] The company employed 638 people, mostly in Lexington, MA.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]
Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.[5]
In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.[6]
The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.
In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.[7]
In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.[8]
In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.
The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.[9] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).[10]
In 2011, its product pipeline focused on gram-negative bacterial infections,[11] Clostridium difficile-associated diarrhea,[12] and respiratory syncytial virus.[13]
Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.[14][15]
|
| |||
|---|---|---|---|
| Corporate directors |
| ||
| Subsidiaries |
| ||
| Products |
| ||
| Facilities |
| ||
| Publications |
| ||
42°25′25.2″N 71°14′32.9″W / 42.423667°N 71.242472°W / 42.423667; -71.242472
